Marine drugs for cancer: surfacing biotechnological innovations from the oceans

This review will discuss the contributions of marine natural molecules, a source only recently found to have pharmaceutical prospects, to the development of anticancer drugs. Of the seven clinically utilized compounds with a marine origin, four are used for the treatment of cancer. The development of these drugs has afforded valuable knowledge and crucial insights to meet the most common challenges in this endeavor, such as toxicity and supply. In this context, the development of these compounds will be discussed herein to illustrate, with successful examples provided by cytarabine, trabectedin, eribulin and brentuximab vedotin, the steps involved in this process as well as the scientific advances and technological innovation potential associated with developing a new drug from marine resources

Marine drugs for cancer: surfacing biotechnological innovations from the oceans

This review will discuss the contributions of marine natural molecules, a source only recently found to have pharmaceutical prospects, to the development of anticancer drugs. Of the seven clinically utilized compounds with a marine origin, four are used for the treatment of cancer. The development of these drugs has afforded valuable knowledge and crucial insights to meet the most common challenges in this endeavor, such as toxicity and supply. In this context, the development of these compounds will be discussed herein to illustrate, with successful examples provided by cytarabine, trabectedin, eribulin and brentuximab vedotin, the steps involved in this process as well as the scientific advances and technological innovation potential associated with developing a new drug from marine resources

BIRC8 (baculoviral IAP repeat containing 8)

BIRC8, also known as ILP-2, is a homologous protein of BIRC4, however, its function has seldom been addressed. Despite the similarity with other Inhibitory Apoptosis Proteins (IAPs), there is evidence that BIRC8 acts in a peculiar manner, by impeding apoptosis induced by BAX without directly inhibiting the activity of caspases. BIRC8 expression has been detected in testis and lymphoblastic normal cells and, furthermore, it has been reported in different cancers, including breast carcinoma, hematological neoplasms, hepatocellular carcinoma, nasopharyngeal carcinoma, and neuroblastoma. However, the specific implications of such protein for treatment and prognosis must be further evaluated. In this review, current data on RNA, DNA, protein and the association of BIRC8 in cancer are presented

BIRC5 (baculoviral IAP repeat containing 5)

BIRC5, also known as survivin, has been implicated in cell cycle progression and apoptosis avoidance. BIRC5 is highly expressed in embryonic tissues, however very low or absent in adult tissues. BIRC5 overexpression has been frequently associated to cancer development, a poor prognosis and chemoresistance. Besides that, different BIRC5 isoforms has been characterized and related to better or worse chemotherapy responses depending on the isoform and the cancer type. So far, many efforts have been conducted in order to deplete BIRC5 in cancer cells, including gene therapy, pharmacological and nanotechnological approaches. In this review, we will discuss the role of BIRC5 in cancer cell biology and its clinical significance, demonstrating its DNA/RNA and protein aspects, also its relevance for diagnosis and prognosis, and advances as a target for the treatment of different cancer types

First-time Isolation of Flavonoids and Cytotoxic Potential of the Amazonian Shrub Ptychopetalum olacoides Benth

In the present study, three flavonoids, 3-O-methylquercetin (1), 3,4'-O-dimethylquercetin (2) and 3,7-O-dimethylquercetin (3) were isolated and characterized for the first time from a methanol extract obtained from the species Ptychopetalum olacoides. The structures of compounds were identified by spectroscopic methods (1D-, 2D-NMR, MS and UV) and confirmed by comparison with the respective literature data. The cytotoxic effect of crude extract was evaluated in vitro against three human cancer cell lines. The results showed a mild cytotoxic activity (IC50 = 45.16 mu g/mL) against breast cancer (MCF-7). However, crude extract did not exhibit any cytotoxic effect against normal cell human fibroblast (MRC-5).FAPERJCoordenação de Aperfeiçoamento de Pessoal de Nível Superior (CAPES)Conselho Nacional de Desenvolvimento Científico e Tecnológico (CNPq)Univ Fed Fluminense, Inst Quim, Dept Quim Organ, Campus Valonguinho, BR-24020141 Niteroi, RJ, BrazilUniv Fed Para, Inst Ciencias Biol, BR-66075110 Belem, Para, BrazilUniv Fed Sao Paulo, Dept Ciencias Mar, BR-11070100 Santos, SP, BrazilUniv Fed Rural Rio de Janeiro, Dept Quim, BR-23897000 Seropedica, RJ, BrazilUniv Fed Sao Paulo, Dept Ciencias Mar, BR-11070100 Santos, SP, BrazilWeb of Scienc

Chromomycin A2 Induces Autophagy in Melanoma Cells

The present study highlights the biological effects of chromomycin A2 toward metastatic melanoma cells in culture. Besides chromomycin A2, chromomycin A3 and demethylchromomycin A2 were also identified from the extract derived from Streptomyces sp., recovered from Paracuru Beach, located in the northeast region of Brazil. the cytotoxic activity of chromomycin A2 was evaluated across a panel of human tumor cell lines, which found IC50 values in the nM-range for exposures of 48 and 72 h. MALME-3M, a metastatic melanoma cell line, showed the highest sensitivity to chromomycin A2 after 48h incubation, and was chosen as a model to investigate this potent cytotoxic effect. Treatment with chromomycin A2 at 30 nM reduced cell proliferation, but had no significant effect upon cell viability. Additionally, chromomycin A2 induced accumulation of cells in G(0)/G(1) phase of the cell cycle, with consequent reduction of S and G(2)/M and unbalanced expression of cyclins. Chromomycin A2 treated cells depicted several cellular fragments resembling autophagosomes and increased expression of proteins LC3-A and LC3-B. Moreover, exposure to chromomycin A2 also induced the appearance of acidic vacuolar organelles in treated cells. These features combined are suggestive of the induction of autophagy promoted by chromomycin A2, a feature not previously described for chromomycins.Conselho Nacional de Desenvolvimento Científico e Tecnológico (CNPq)Fundacao Cearense de Apoio ao Desenvolvimento Cientifico e Tecnologico (FUNCAP-Programa Areas Estrategicas)Univ Fed Ceara, Inst Marine Sci, BR-60165081 Fortaleza, Ceara, BrazilUniv Fed Ceara, Dept Physiol & Pharmacol, BR-60430270 Fortaleza, Ceara, BrazilUniversidade Federal de São Paulo, Dept Marine Sci, BR-11030400 São Paulo, BrazilUniv Fed Ceara, Dept Organ & Inorgan Chem, BR-60021970 Fortaleza, Ceara, BrazilFdn MEDINA, Ctr Excelencia Invest Medicamentos Innovadores An, Granada 18016, SpainUniversidade Federal de São Paulo, Dept Marine Sci, BR-11030400 São Paulo, BrazilWeb of Scienc

XIAP (X-linked inhibitor of apoptosis)

X-linked inhibitor of apoptosis (XIAP), also referred to as BIRC4 or IAP3, is one of the most studied members among the proteins known as Inhibitors of Apoptosis Proteins (IAPs). This protein family portrays its main role by preventing apoptotic cell death through direct or indirect inhibition of caspase activity. All members of the IAPs carry at least one BIR domain in their structure, which are generally responsible for caspase interaction. XIAP has three BIR domains, enabling interaction with both initiation and effector caspases. Moreover, it is also structured with a RING finger domain, which functions as a ubiquitin ligase (E3), and one UBA domain, for binding to ubiquitin, further rendering XIAP a central role in the ubiquitination process and, thus, implicating such IAP in multiple signaling pathways, including cell death, autophagy, immunity, inflammation, cell cycle, and cell migration. XIAP overexpression is found in a variety of cancer types and is frequently associated with chemoresistance and increased risk of relapse. Furthermore, there are many evidences that XIAP inhibition may sensitize tumor cells to chemotherapy agents, which make this protein a potential target in cancer

Cytotoxic lipidic α-amino acids from the zoanthid Protopalythoa variabilis from the Northeastern coast of Brazil

Two lipidic α-amino acids 1a and 1b were isolated from the zoanthid Protopalythoa variabilis using a bioguided fractionation for cytotoxic activity. The structures of the metabolites were determined by spectroscopic methods, including NMR (nuclear magnetic resonance) ¹H e 13C, IR (infrared) and high resolution mass spectrometry (positive mode). The cytotoxic activity of the crude extract, as well as of the mixture of 1a and 1b were measured in vitro using the MTT assay for four human tumor cell lines. This finding has important biological and chemical implications for this type of compound. This is the first report of lipidic α-amino acids from natural sources, as well as of their cytotoxic activity.Dois α-aminoácidos lipídicos 1a e 1b foram isolados do zoantídeo Protopalythoa variabilis através de fracionamento guiado pela atividade citotóxica. As estruturas foram determinadas por diferentes métodos espectroscópicos, tais como, RMN (ressonância magnética nuclear) ¹H e 13C, IV (infravermelho) e espectrometria de massa de alta resolução (modo positivo). A atividade citotóxica dos extratos, das frações e 1a/1b foi avaliada in vitro através do teste do MTT contra quatro linhagens de células tumorais. Este achado tem implicações biológicas e químicas importantes para essa classe de compostos. Este é o primeiro relato de α-aminoácidos lipídicos a partir de uma fonte natural, bem como de sua atividade citotóxica.CNPqFINEPInstitute Claude Bernar

Structure Elucidation and Anticancer Activity of 7-Oxostaurosporine Derivatives from the Brazilian Endemic Tunicate Eudistoma vannamei

The present study reports the identification of two new staurosporine derivatives, 2-hydroxy-7-oxostaurosporine (1) and 3-hydroxy-7-oxostaurosporine (2), obtained from mid-polar fractions of an aqueous methanol extract of the tunicate Eudistoma vannamei, endemic to the northeast coast of Brazil. The mixture of 1 and 2 displayed IC50 values in the nM range and was up to 14 times more cytotoxic than staurosporine across a panel of tumor cell lines, as evaluated using the MTT assay.CNPqCAPESInCBFAPES

Antimicrobial resistance among migrants in Europe: a systematic review and meta-analysis

BACKGROUND: Rates of antimicrobial resistance (AMR) are rising globally and there is concern that increased migration is contributing to the burden of antibiotic resistance in Europe. However, the effect of migration on the burden of AMR in Europe has not yet been comprehensively examined. Therefore, we did a systematic review and meta-analysis to identify and synthesise data for AMR carriage or infection in migrants to Europe to examine differences in patterns of AMR across migrant groups and in different settings. METHODS: For this systematic review and meta-analysis, we searched MEDLINE, Embase, PubMed, and Scopus with no language restrictions from Jan 1, 2000, to Jan 18, 2017, for primary data from observational studies reporting antibacterial resistance in common bacterial pathogens among migrants to 21 European Union-15 and European Economic Area countries. To be eligible for inclusion, studies had to report data on carriage or infection with laboratory-confirmed antibiotic-resistant organisms in migrant populations. We extracted data from eligible studies and assessed quality using piloted, standardised forms. We did not examine drug resistance in tuberculosis and excluded articles solely reporting on this parameter. We also excluded articles in which migrant status was determined by ethnicity, country of birth of participants' parents, or was not defined, and articles in which data were not disaggregated by migrant status. Outcomes were carriage of or infection with antibiotic-resistant organisms. We used random-effects models to calculate the pooled prevalence of each outcome. The study protocol is registered with PROSPERO, number CRD42016043681. FINDINGS: We identified 2274 articles, of which 23 observational studies reporting on antibiotic resistance in 2319 migrants were included. The pooled prevalence of any AMR carriage or AMR infection in migrants was 25·4% (95% CI 19·1-31·8; I2 =98%), including meticillin-resistant Staphylococcus aureus (7·8%, 4·8-10·7; I2 =92%) and antibiotic-resistant Gram-negative bacteria (27·2%, 17·6-36·8; I2 =94%). The pooled prevalence of any AMR carriage or infection was higher in refugees and asylum seekers (33·0%, 18·3-47·6; I2 =98%) than in other migrant groups (6·6%, 1·8-11·3; I2 =92%). The pooled prevalence of antibiotic-resistant organisms was slightly higher in high-migrant community settings (33·1%, 11·1-55·1; I2 =96%) than in migrants in hospitals (24·3%, 16·1-32·6; I2 =98%). We did not find evidence of high rates of transmission of AMR from migrant to host populations. INTERPRETATION: Migrants are exposed to conditions favouring the emergence of drug resistance during transit and in host countries in Europe. Increased antibiotic resistance among refugees and asylum seekers and in high-migrant community settings (such as refugee camps and detention facilities) highlights the need for improved living conditions, access to health care, and initiatives to facilitate detection of and appropriate high-quality treatment for antibiotic-resistant infections during transit and in host countries. Protocols for the prevention and control of infection and for antibiotic surveillance need to be integrated in all aspects of health care, which should be accessible for all migrant groups, and should target determinants of AMR before, during, and after migration. FUNDING: UK National Institute for Health Research Imperial Biomedical Research Centre, Imperial College Healthcare Charity, the Wellcome Trust, and UK National Institute for Health Research Health Protection Research Unit in Healthcare-associated Infections and Antimictobial Resistance at Imperial College London